Modulation of the endocannabinoid system: Vulnerability factor and new treatment target for stimulant addiction

Frontiers in Psychiatry

Volumn 4, Issue SEP, 2013, Pages

  Olière, Stéphanie ^a   Joliette Riopel, Antoine ^a   Potvin, Stéphane ^b,c   Jutras Aswad, Didier ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE MONTRÉAL   (Canada)

Author keywords

Addiction; Cannabinoids or endocannabinoids; Cannabis; Cocaine; Psychostimulants; Stimulants

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ACYLGLYCEROL LIPASE; AMPHETAMINE; ANALGESIC AGENT; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; COCAINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; JZL 184; KETAMINE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NEUROTRANSMITTER; PF 3845; PSYCHOSTIMULANT AGENT; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1;

ABSTINENCE; ADDICTION; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANTERIOR CINGULATE; ANTICONVULSANT ACTIVITY; ANTIEMETIC ACTIVITY; ARTICLE; CANNABIS ADDICTION; CNR1 GENE; COCAINE DEPENDENCE; DNA POLYMORPHISM; DOPAMINERGIC SYSTEM; DRUG SEEKING BEHAVIOR; DRUG TOLERABILITY; EMOTIONAL STRESS; ENZYME ACTIVITY; EUPHORIA; GABAERGIC SYSTEM; GENE; GENE DELETION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; INTRAVENOUS DRUG ABUSE; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NEUROTRANSMITTER UPTAKE; NONHUMAN; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHOSTIMULANT ADDICTION; REINFORCEMENT; RELAPSE; REWARD; SELF STIMULATION; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME;

EID: 84885349034     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00109     Document Type: Article

References (294)

1. UNODC. World Drug Report 2009. Vienna: United Nations Office on Drugs and Crime (2009).
2. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The DASIS Report: Geographic Differences in Substance Abuse Treatment Admissions for Methamphetamine/Amphetamine and Marijuana: 2005. Rockville, MD (2008).
3. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet (2012) 379:55-70. doi:10.1016/S0140-6736(11)61138-0.
4. UNODC. World Drug Report. Vienna: United Nations Publication (2012).
5. Ben Diane MK, Feroni I, Poncet M, Obadia Y. Chief health risks associated with intravenous heroin and cocaine abuse. Presse Med (2000) 29:453-7.
6. Arendt M, Munk-Jorgensen P, Sher L, Jensen SO. Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. Drug Alcohol Depend (2011) 114(2-3):134-9. doi:10.1016/j.drugalcdep.2010.09.013.
7. Pavarin R, Lugoboni F, Mathewson S, Ferrari AM, Guizzardi G, Quaglio G. Cocaine-related medical and trauma problems: a consecutive series of 743 patients from a multicentre study in Italy. Eur J Emerg Med (2011) 18(4):208-14. doi:10.1097/MEJ.0b013e3283440f25.
8. Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs (2004) 64:1547-73. doi:10.2165/00003495-200464140-00004.
9. Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry (2005) 18:265-70. doi:10.1097/01.yco.0000165596.98552.02.
10. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol (2008) 11:425-38. doi:10.1017/S1461145707008097.
11. Christopher Pierce R, O'Brien CP, Kenny PJ, Vanderschuren LJ. Rational development of addiction pharmacotherapies: successes, failures, and prospects. Cold Spring Harb Perspect Med (2012) 2:a012880. doi:10.1101/cshperspect.a012880.
12. Lima MS, Reisser AA, Soares BG, Farrell M. Antidepressants for cocaine dependence. Cochrane Database Syst Rev (2003):CD002950.
13. Amato L, Minozzi S, Pani PP, Davoli M. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev (2007):CD006306.
14. Minozzi S, Amato L, Davoli M, Farrell M, Lima Reisser AA, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev (2008):CD006754. doi:10.1002/14651858.CD006754.pub2.
15. Xi ZX, Gardner EL. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev (2008) 1:303-27. doi:10.2174/1874473710801030303.
16. Perez-Mana C, Castells X, Vidal X, Casas M, Capella D. Efficacy of indirect dopamine agonists for psychostimulant dependence: a systematic review and meta-analysis of randomized controlled trials. J Subst Abuse Treat (2011) 40:109-22. doi:10.1016/j.jsat.2010.08.012.
17. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry (2009) 66:1116-23. doi:10.1001/archgenpsychiatry.2009.128.
18. Ries RK, Fiellin DA, Miller SC, Saitz R. Principles of Addiction Medecine. 4th ed. Philadelphia: Lippincott Williams & Wilkins (2009). p. 707-22.
19. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav (2005) 81:263-84. doi:10.1016/j.pbb.2005.01.032.
20. Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol (2009) 71:283-306. doi:10.1146/annurev.physiol.010908.163149.
21. Lutz B. Endocannabinoid signals in the control of emotion. Curr Opin Pharmacol (2009) 9:46-52. doi:10.1016/j.coph.2008.12.001.
22. Jutras-Aswad D, Zang G, Bruneau J. Cannabis use correlates of syringe sharing among injection drug users. Am J Addict (2010) 19:231-7. doi:10.1111/j.1521-0391.2010.00031.x.
23. WHO. Neuroscience of psychoactive substance use and dependence. Geneva: World Health Organization (2004).
24. Hyman SM, Fox H, Hong KI, Doebrick C, Sinha R. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. Exp Clin Psychopharmacol (2007) 15:134-43. doi:10.1037/1064-1297.15.2.134.
25. O'Brien CP, Childress AR, Ehrman R, Robbins SJ. Conditioning factors in drug abuse: can they explain compulsion? J Psychopharmacol (1998) 12:15-22. doi:10.1177/026988119801200103.
26. Sinha R, Lacadie C, Skudlarski P, Fulbright RK, Rounsaville BJ, Kosten TR, et al. Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study. Psychopharmacology (Berl) (2005) 183:171-80. doi:10.1007/s00213-005-0147-8.
27. Lingford-Hughes AR, Davies SJ, McIver S, Williams TM, Daglish MR, Nutt DJ. Addiction. Br Med Bull (2003) 65:209-22. doi:10.1093/bmb/65.1.209.
28. Robinson TE, Berridge KC. Addiction. Annu Rev Psychol (2003) 54:25-53. doi:10.1146/annurev.psych.54.101601.145237.
29. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry (2005) 162:1403-13. doi:10.1176/appi.ajp.162.8.1403.
30. Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW. Review. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci (2008) 363:3125-35. doi:10.1098/rstb.2008.0089.
31. Feltenstein MW, See RE. The neurocircuitry of addiction: an overview. Br J Pharmacol (2008) 154:261-74. doi:10.1038/bjp.2008.51.
32. Chen PC, Lao CL, Chen JC. The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5. J Neurochem (2009) 110:1180-90. doi:10.1111/j.1471-4159.2009.06209.x.
33. Di Chiara G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res (2002) 137:75-114. doi:10.1016/S0166-4328(02)00286-3.
34. Meil WM, See RE. Lesions of the basolateral amygdala abolish the ability of drug associated cues to reinstate responding during withdrawal from self-administered cocaine. Behav Brain Res (1997) 87:139-48. doi:10.1016/S0166-4328(96)02270-X.
35. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry (1999) 156:11-8.
36. Robbins TW, Everitt BJ, Nutt DJ. Introduction. The neurobiology of drug addiction: new vistas. Philos Trans R Soc Lond B Biol Sci (2008) 363:3109-11. doi:10.1098/rstb.2008.0108.
37. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry (2002) 159:1642-52. doi:10.1176/appi.ajp.159.10.1642.
38. Koob GF, Swerdlow NR. The functional output of the mesolimbic dopamine system. Ann N Y Acad Sci (1988) 537:216-27. doi:10.1111/j.1749-6632.1988.tb42108.x.
39. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature (1997) 386:827-30. doi:10.1038/386827a0.
40. Fowler JS, Volkow ND, Wang GJ, Gatley SJ, Logan J. [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol (2001) 28:561-72. doi:10.1016/S0969-8051(01)00211-6.
41. Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol (2000) 406:1-13. doi:10.1016/S0014-2999(00)00639-7.
42. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol (2003) 479:23-40. doi:10.1016/j.ejphar.2003.08.054.
43. Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta (1993) 1144:249-63. doi:10.1016/0005-2728(93)90109-S.
44. Howell LL, Kimmel HL. Monoamine transporters and psychostimulant addiction. Biochem Pharmacol (2008) 75:196-217. doi:10.1016/j.bcp.2007.08.003.
45. Barr AM, Panenka WJ, Macewan GW, Thornton AE, Lang DJ, Honer WG, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci (2006) 31:301-13.
46. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci (1998) 1:132-7. doi:10.1038/381.
47. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, et al. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci U S A (1998) 95:7699-704. doi:10.1073/pnas.95.13.7699.
48. Lee B, Tiefenbacher S, Platt DM, Spealman RD. Role of the hypothalamic-pituitary-adrenal axis in reinstatement of cocaine-seeking behavior in squirrel monkeys. Psychopharmacology (Berl) (2003) 168:177-83. doi:10.1007/s00213-003-1391-4.
49. Arnold JC. The role of endocannabinoid transmission in cocaine addiction. Pharmacol Biochem Behav (2005) 81:396-406. doi:10.1016/j.pbb.2005.02.015.
50. Backstrom P, Hyytia P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology (2006) 31:778-86. doi:10.1038/sj.npp.1300845.
51. Lingford-Hughes A, Nutt D. Neurobiology of addiction and implications for treatment. Br J Psychiatry (2003) 182:97-100. doi:10.1192/bjp.182.2.97.
52. Broderick PA, Olabisi OA, Rahni DN, Zhou Y. Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies. Prog Neuropsychopharmacol Biol Psychiatry (2004) 28:547-57. doi:10.1016/j.pnpbp.2004.01.007.
53. Filip M. Role of serotonin (5-HT)2 receptors in cocaine self-administration and seeking behavior in rats. Pharmacol Rep (2005) 57:35-46.
54. Wee S, Wang Z, He R, Zhou J, Kozikowski AP, Woolverton WL. Role of the increased noradrenergic neurotransmission in drug self-administration. Drug Alcohol Depend (2006) 82:151-7. doi:10.1016/j.drugalcdep.2005.09.002.
55. Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, Wei HB, et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S A (2001) 98:5300-5. doi:10.1073/pnas.091039298.
56. Hall FS, Li XF, Sora I, Xu F, Caron M, Lesch KP, et al. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience (2002) 115:153-61. doi:10.1016/S0306-4522(02)00379-2.
57. Shaham Y, Erb S, Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Brain Res Rev (2000) 33:13-33. doi:10.1016/S0165-0173(00)00024-2.
58. Weinshenker D, Schroeder JP. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology (2007) 32:1433-51. doi:10.1038/sj.npp.1301263.
59. Gaval-Cruz M, Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv (2009) 9:175-87. doi:10.1124/mi.9.4.6.
60. Leri F, Flores J, Rodaros D, Stewart J. Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. J Neurosci (2002) 22:5713-8.
61. Smith RJ, Aston-Jones G. alpha(2) Adrenergic and imidazoline receptor agonists prevent cue-induced cocaine seeking. Biol Psychiatry (2011) 70:712-9. doi:10.1016/j.biopsych.2011.06.010.
62. Parsons LH, Weiss F, Koob GF. Serotonin1b receptor stimulation enhances dopamine-mediated reinforcement. Psychopharmacology (Berl) (1996) 128:150-60. doi:10.1007/s002130050120.
63. Tzschentke TM, Schmidt WJ. Glutamatergic mechanisms in addiction. Mol Psychiatry (2003) 8:373-82. doi:10.1038/sj.mp.4001269.
64. Kalivas PW, Lalumiere RT, Knackstedt L, Shen H. Glutamate transmission in addiction. Neuropharmacology (2009) 56(Suppl 1):169-73. doi:10.1016/j.neuropharm.2008.07.011.
65. Sarti F, Borgland SL, Kharazia VN, Bonci A. Acute cocaine exposure alters spine density and long-term potentiation in the ventral tegmental area. Eur J Neurosci (2007) 26:749-56. doi:10.1111/j.1460-9568.2007.05689.x.
66. Chen Q, Xiong X, Lee TH, Liu Y, Wetsel WC, Zhang X. Neural plasticity and addiction: integrin-linked kinase and cocaine behavioral sensitization. J Neurochem (2008) 107:679-89. doi:10.1111/j.1471-4159.2008.05619.x.
67. Knackstedt LA, Kalivas PW. Glutamate and reinstatement. Curr Opin Pharmacol (2009) 9:59-64. doi:10.1016/j.coph.2008.12.003.
68. Novak M, Halbout B, O'Connor EC, Rodriguez Parkitna J, Su T, Chai M, et al. Incentive learning underlying cocaine-seeking requires mGluR5 receptors located on dopamine D1 receptor-expressing neurons. J Neurosci (2010) 30:11973-82. doi:10.1523/JNEUROSCI.2550-10.2010.
69. Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, et al. Neuroadaptation in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci (2003) 6:743-9. doi:10.1038/nn1069.
70. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci (2003) 23:3531-7.
71. Cornish JL, Kalivas PW. Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. J Neurosci (2000) 20:RC89.
72. McFarland K, Davidge SB, Lapish CC, Kalivas PW. Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J Neurosci (2004) 24:1551-60. doi:10.1523/JNEUROSCI.4177-03.2004.
73. Backstrom P, Hyytia P. Involvement of AMPA/kainate, NMDA, and mGlu5 receptors in the nucleus accumbens core in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl) (2007) 192:571-80. doi:10.1007/s00213-007-0753-8.
74. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology (2004) 47(Suppl 1):227-41. doi:10.1016/j.neuropharm.2004.06.032.
75. Ito I, Kimura T, Watanabe S, Kirino Y, Ito E. Modulation of two oscillatory networks in the peripheral olfactory system by gamma-aminobutyric acid, glutamate, and acetylcholine in the terrestrial slug Limax marginatus. J Neurobiol (2004) 59:304-18. doi:10.1002/neu.10328.
76. Di Ciano P, Cardinal RN, Cowell RA, Little SJ, Everitt BJ. Differential involvement of NMDA, AMPA/kainate, and dopamine receptors in the nucleus accumbens core in the acquisition and performance of pavlovian approach behavior. J Neurosci (2001) 21:9471-7.
77. Kalivas PW, McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl) (2003) 168:44-56. doi:10.1007/s00213-003-1393-2.
78. Robbins TW, Everitt BJ. Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol (1996) 6:228-36. doi:10.1016/S0959-4388(96)80077-8.
79. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) (1999) 146:373-90. doi:10.1007/PL00005483.
80. Rogers RD, Ramnani N, Mackay C, Wilson JL, Jezzard P, Carter CS, et al. Distinct portions of anterior cingulate cortex and medial prefrontal cortex are activated by reward processing in separable phases of decision-making cognition. Biol Psychiatry (2004) 55:594-602. doi:10.1016/j.biopsych.2003.11.012.
81. Dom G, Hulstijn W, Sabbe B. Differences in impulsivity and sensation seeking between early- and late-onsetalcoholics. Addict Behav (2006) 31:298-308. doi:10.1016/j.addbeh.2005.05.009.
82. Yucel M, Lubman DI. Neurocognitive and neuroimaging evidence of behavioural dysregulation in human drug addiction: implications for diagnosis, treatment and prevention. Drug Alcohol Rev (2007) 26:33-9. doi:10.1080/09595230601036978.
83. Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F, et al. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry (2001) 58:334-41. doi:10.1001/archpsyc.58.4.334.
84. Sinha R, Lacadie C, Skudlarski P, Wexler BE. Neural circuits underlying emotional distress in humans. Ann N Y Acad Sci (2004) 1032:254-7. doi:10.1196/annals.1314.032.
85. Ersche KD, Barnes A, Jones PS, Morein-Zamir S, Robbins TW, Bullmore ET. Abnormal structure of frontostriatal brain systems is associated with aspects of impulsivity and compulsivity in cocaine dependence. Brain (2011) 134:2013-24. doi:10.1093/brain/awr138.
86. Xu J, Devito EE, Worhunsky PD, Carroll KM, Rounsaville BJ, Potenza MN. White matter integrity is associated with treatment outcome measures in cocaine dependence. Neuropsychopharmacology (2010) 35:1541-9. doi:10.1038/npp.2010.25.
87. Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. Neuroimage (2002) 16:331-48. doi:10.1006/nimg.2002.1087.
88. Sinha R, Rounsaville BJ. Sex differences in depressed substance abusers. J Clin Psychiatry (2002) 63:616-27. doi:10.4088/JCP.v63n0715.
89. Tanda G. Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence. Pharmacol Res (2007) 56:406-17. doi:10.1016/j.phrs.2007.09.001.
90. Labigalini E Jr, Rodrigues LR, Da Silveira DX. Therapeutic use of cannabis by crack addicts in Brazil. J Psychoactive Drugs (1999) 31:451-5. doi:10.1080/02791072.1999.10471776.
91. Aharonovich E, Liu X, Samet S, Nunes E, Waxman R, Hasin D. Postdischarge cannabis use and its relationship to cocaine, alcohol, and heroin use: a prospective study. Am J Psychiatry (2005) 162:1507-14. doi:10.1176/appi.ajp.162.8.1507.
92. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 58:389-462. doi:10.1124/pr.58.3.2.
93. Herkenham M, Lynn A, Little M, Johnson M, Melvin L, De Costa B, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 87:1932. doi:10.1073/pnas.87.5.1932.
94. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci (1990) 13:420-3. doi:10.1016/0166-2236(90)90124-S.
95. Herkenham M, Lynn AB, De Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res (1991) 547:267-74. doi:10.1016/0006-8993(91)90970-7.
96. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci (1991) 11:563-83.
97. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med (2001) 7:827-32. doi:10.1038/89953.
98. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol (2002) 68:247-86. doi:10.1016/S0301-0082(02)00080-1.
99. Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol (2005) 168:327-65. doi:10.1007/3-540-26573-2_11.
100. Vaughan CW, Christie MJ. Retrograde signalling by endocannabinoids. Handb Exp Pharmacol (2005) 168:367-83. doi:10.1007/3-540-26573-2_12.
101. Kano H, Niranjan A, Novotny J Jr, Bhatnagar J, Flickinger JC, Lunsford LD. Radiosurgery for desmoplastic melanoma of the head and neck using the Leksell Gamma Knife Perfexion technology: a case report. Stereotact Funct Neurosurg (2009) 87:61-5. doi:10.1159/000195721.
102. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-5. doi:10.1038/365061a0.
103. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 232:54-61. doi:10.1111/j.1432-1033.1995.tb20780.x.
104. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol (2003) 461:27-34. doi:10.1016/S0014-2999(03)01295-0.
105. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci (2006) 1074:514-36. doi:10.1196/annals.1369.052.
106. Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol (2007) 5:73-80. doi:10.2174/157015907780866884.
107. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS ONE (2008) 3:e1640. doi:10.1371/journal.pone.0001640.
108. Witting A, Walter L, Wacker J, Moller T, Stella N. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci U S A (2004) 101:3214-9. doi:10.1073/pnas.0306707101.
109. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 13:492-7. doi:10.1038/nm1561.
110. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br J Pharmacol (2008) 153:240-51. doi:10.1038/sj.bjp.0707584.
111. Racz I, Bilkei-Gorzo A, Markert A, Stamer F, Gothert M, Zimmer A. Anandamide effects on 5-HT(3) receptors in vivo. Eur J Pharmacol (2008) 596:98-101. doi:10.1016/j.ejphar.2008.08.012.
112. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 160:467-79. doi:10.1111/j.1476-5381.2010.00729.x.
113. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia (2010) 58:1017-30. doi:10.1002/glia.20983.
114. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem (2002) 80:448-56. doi:10.1046/j.0022-3042.2001.00716.x.
115. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther (2005) 106:133-45. doi:10.1016/j.pharmthera.2004.11.005.
116. Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience (2006) 139:1405-15. doi:10.1016/j.neuroscience.2006.02.074.
117. Brown AJ. Low-carb diets, fasting and euphoria: is there a link between ketosis and gamma-hydroxybutyrate (GHB)? Med Hypotheses (2007) 68:268-71. doi:10.1016/j.mehy.2006.07.043.
118. Godlewski G, Offertaler L, Osei-Hyiaman D, Mo FM, Harvey-White J, Liu J, et al. The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca2+-activated K+ channels. J Pharmacol Exp Ther (2009) 328:351-61. doi:10.1124/jpet.108.144717.
119. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol (2007) 152:825-31. doi:10.1038/sj.bjp.0707419.
120. Kapur A, Hurst DP, Fleischer D, Whitnell R, Thakur GA, Makriyannis A, et al. Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol (2007) 71:1512-24. doi:10.1124/mol.107.034645.
121. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol (2007) 152:1092-101. doi:10.1038/sj.bjp.0707460.
122. Giuffrida A, Seillier A. New insights on endocannabinoid transmission in psychomotor disorders. Prog Neuropsychopharmacol Biol Psychiatry (2012) 38:51-8. doi:10.1016/j.pnpbp.2012.04.002.
123. Sylantyev S, Jensen TP, Ross RA, Rusakov DA. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A (2013) 110:5193-8. doi:10.1073/pnas.1211204110.
124. Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov (2009) 8:55-68. doi:10.1038/nrd2757.
125. Mezey E, Toth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A (2000) 97:3655-60. doi:10.1073/pnas.97.7.3655.
126. Szolcsanyi J. Anandamide and the question of its functional role for activation of capsaicin receptors. Trends Pharmacol Sci (2000) 21:203-4. doi:10.1016/S0165-6147(00)01484-X.
127. De Petrocellis L, Harrison S, Bisogno T, Tognetto M, Brandi I, Smith GD, et al. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem (2001) 77:1660-3. doi:10.1046/j.1471-4159.2001.00406.x.
128. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A (2002) 99:8400-5. doi:10.1073/pnas.122196999.
129. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci (2008) 11:152-9. doi:10.1038/nn2042.
130. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci (2002) 5:446-51.
131. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci (2002) 22:6900-7.
132. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron (2001) 29:729-38. doi:10.1016/S0896-6273(01)00247-1.
133. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 410:588-92. doi:10.1038/35069076.
134. Kreitzer AC, Regehr WG. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci (2001) 21:RC174.
135. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946-9. doi:10.1126/science.1470919.
136. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 215:89-97. doi:10.1006/bbrc.1995.2437.
137. Hanus L, Abu-LafiS, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A (2001) 98:3662-5. doi:10.1073/pnas.061029898.
138. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther (2002) 301:1020-4. doi:10.1124/jpet.301.3.1020.
139. Wilson RI, Kunos G, Nicoll RA. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron (2001) 31:453-62. doi:10.1016/S0896-6273(01)00372-5.
140. Okamoto Y, Wang J, Morishita J, Ueda N. Biosynthetic pathways of the endocannabinoid anandamide. Chem Biodivers (2007) 4:1842-57. doi:10.1002/cbdv.200790155.
141. Tanimura A, Yamazaki M, Hashimotodani Y, Uchigashima M, Kawata S, Abe M, et al. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron (2010) 65:320-7. doi:10.1016/j.neuron.2010.01.021.
142. Fride E. Endocannabinoids in the central nervous system: from neuronal networks to behavior. Curr Drug Targets CNS Neurol Disord (2005) 4:633-42. doi:10.2174/156800705774933069.
143. Hillard CJ. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat (2000) 61:3-18. doi:10.1016/S0090-6980(00)00051-4.
144. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 384:83-7. doi:10.1038/384083a0.
145. Nomura DK, Blankman JL, Simon GM, Fujioka K, Issa RS, Ward AM, et al. Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol (2008) 4:373-8. doi:10.1038/nchembio.86.
146. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol (2007) 14:1347-56. doi:10.1016/j.chembiol.2007.11.006.
147. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci (2010) 13:951-7. doi:10.1038/nn.2601.
148. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem (2005) 74:411-32. doi:10.1146/annurev.biochem.74.082803.133450.
149. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2005) 313:352-8. doi:10.1124/jpet.104.078980.
150. Straiker A, Hu SS, Long JZ, Arnold A, Wager-Miller J, Cravatt BF, et al. Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. Mol Pharmacol (2009) 76:1220-7. doi:10.1124/mol.109.059030.
151. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol (2009) 16:411-20. doi:10.1016/j.chembiol.2009.02.013.
152. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev (2006) 12:21-38. doi:10.1111/j.1527-3458.2006.00021.x.
153. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav (2011) 98:21-7. doi:10.1016/j.pbb.2010.12.002.
154. Naidu PS, Kinsey SG, Guo TL, Cravatt BF, Lichtman AH. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther (2010) 334:182-90. doi:10.1124/jpet.109.164806.
155. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A (2009) 106:20270-5. doi:10.1073/pnas.0909411106.
156. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci (2010) 13:1113-9. doi:10.1038/nn.2616.
157. Chanda PK, Gao Y, Mark L, Btesh J, Strassle BW, Lu P, et al. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol (2010) 78:996-1003. doi:10.1124/mol.110.068304.
158. Pan B, Wang W, Zhong P, Blankman JL, Cravatt BF, Liu QS. Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice. J Neurosci (2011) 31:13420-30. doi:10.1523/JNEUROSCI.2075-11.2011.
159. Watson SJ, Benson JA Jr, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry (2000) 57:547-52. doi:10.1001/archpsyc.57.6.547.
160. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res (2006) 39:421-9. doi:10.1590/S0100-879X2006000400001.
161. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) (2002) 164:61-70. doi:10.1007/s00213-002-1169-0.
162. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol (2001) 23:1-11. doi:10.1016/S0892-0362(00)00119-7.
163. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ (2002) 325:1212-3. doi:10.1136/bmj.325.7374.1212.
164. Kandel DB. Does marijuana use cause the use of other drugs? JAMA (2003) 289:482-3. doi:10.1001/jama.289.4.482.
165. Huizink AC, Mulder EJ. Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. Neurosci Biobehav Rev (2006) 30:24-41. doi:10.1016/j.neubiorev.2005.04.005.
166. D'Souza DC, Perry E, Macdougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology (2004) 29:1558-72. doi:10.1038/sj.npp.1300496.
167. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology (2008) 33:2505-16. doi:10.1038/sj.npp.1301643.
168. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther (1992) 260:201-9.
169. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs (2000) 60:1303-14. doi:10.2165/00003495-200060060-00005.
170. Guimaraes FS, De Aguiar JC, Mechoulam R, Breuer A. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol (1994) 25:161-4. doi:10.1016/0306-3623(94)90027-2.
171. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res (2005) 30:1037-43. doi:10.1007/s11064-005-6978-1.
172. Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry (2006) 30:1466-71. doi:10.1016/j.pnpbp.2006.06.004.
173. Hermann D, Sartorius A, Welzel H, Walter S, Skopp G, Ende G, et al. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry (2007) 61:1281-9. doi:10.1016/j.biopsych.2006.08.027.
174. El-Alfy AT, Ivey K, Robinson K, Ahmed S, Radwan M, Slade D, et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav (2010) 95:434-42. doi:10.1016/j.pbb.2010.03.004.
175. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol (2010) 13:861-76. doi:10.1017/S1461145709990605.
176. Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol (2010) 159:122-8. doi:10.1111/j.1476-5381.2009.00521.x.
177. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol (2007) 150:613-23. doi:10.1038/sj.bjp.0707133.
178. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2008) 153:199-215. doi:10.1038/sj.bjp.0707442.
179. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci (2008) 28:6231-8. doi:10.1523/JNEUROSCI.0504-08.2008.
180. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 134:845-52. doi:10.1038/sj.bjp.0704327.
181. Pandolfo P, Silveirinha V, Dos Santos-Rodrigues A, Venance L, Ledent C, Takahashi RN, et al. Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. Eur J Pharmacol (2011) 655:38-45. doi:10.1016/j.ejphar.2011.01.013.
182. Murillo-Rodriguez E, Palomero-Rivero M, Millan-Aldaco D, Mechoulam R, Drucker-Colin R. Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats. Life Sci (2011) 88:504-11. doi:10.1016/j.lfs.2011.01.013.
183. Kathmann M, Flau K, Redmer A, Trankle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol (2006) 372:354-61. doi:10.1007/s00210-006-0033-x.
184. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A (2006) 103:7895-900. doi:10.1073/pnas.0511232103.
185. Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci (2001) 21:823-33.
186. Schoffelmeer AN, Hogenboom F, Wardeh G, De Vries TJ. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology (2006) 51:773-81. doi:10.1016/j.neuropharm.2006.05.019.
187. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A (1998) 95:8268-73. doi:10.1073/pnas.95.14.8268.
188. Hallak JE, Dursun SM, Bosi DC, De Macedo LR, Machado-De-Sousa JP, Abrao J, et al. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry (2011) 35:198-202. doi:10.1016/j.pnpbp.2010.11.002.
189. Campos AC, Guimaraes FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) (2008) 199:223-30. doi:10.1007/s00213-008-1168-x.
190. Alves FH, Crestani CC, Gomes FV, Guimaraes FS, Correa FM, Resstel LB. Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors. Pharmacol Res (2010) 62:228-36. doi:10.1016/j.phrs.2010.05.003.
191. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol (2010) 159:950-7. doi:10.1111/j.1476-5381.2009.00589.x.
192. Soares Vde P, Campos AC, Bortoli VC, Zangrossi H Jr, Guimaraes FS, Zuardi AW. Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res (2010) 213:225-9. doi:10.1016/j.bbr.2010.05.004.
193. Gomes FV, Reis DG, Alves FH, Correa FM, Guimaraes FS, Resstel LB. Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors. J Psychopharmacol (2012) 26:104-13. doi:10.1177/0269881110389095.
194. Guimaraes FS, Chiaretti TM, GraeffFG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) (1990) 100:558-9. doi:10.1007/BF02244012.
195. Granjeiro EM, Gomes FV, Guimaraes FS, Correa FM, Resstel LB. Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. Pharmacol Biochem Behav (2011) 99:743-8. doi:10.1016/j.pbb.2011.06.027.
196. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry (2009) 66:95-105. doi:10.1001/archgenpsychiatry.2008.519.
197. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology (2004) 29:417-26. doi:10.1038/sj.npp.1300340.
198. Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol (2011) 25:121-30. doi:10.1177/0269881110379283.
199. Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol (2010) 13(4): 421-32. doi:10.1017/S1461145709990617.
200. Pessoa L. On the relationship between emotion and cognition. Nat Rev Neurosci (2008) 9:148-58. doi:10.1038/nrn2317.
201. Casarotto PC, Gomes FV, Resstel LB, Guimaraes FS. Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol (2010) 21:353-8. doi:10.1097/FBP.0b013e32833b33c5.
202. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) (2012) 219(3):859-73.
203. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol (2002) 42:11S-9S.
204. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis (2005) 19:96-107. doi:10.1016/j.nbd.2004.11.009.
205. Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord (2005) 4:677-84. doi:10.2174/156800705774933005.
206. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O'Carroll C, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry (2009) 66:442-51. doi:10.1001/archgenpsychiatry.2009.17.
207. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2010) 35:764-74. doi:10.1038/npp.2009.184.
208. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, et al. Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry (2008) 64:966-73. doi:10.1016/j.biopsych.2008.05.011.
209. Fox HC, Hong KI, Siedlarz K, Sinha R. Enhanced sensitivity to stress and drug/alcohol craving in abstinent cocaine-dependent individuals compared to social drinkers. Neuropsychopharmacology (2008) 33:796-805. doi:10.1038/sj.npp.1301470.
210. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med (2008) 14:923-30. doi:10.1038/nm.f.1869.
211. Lalumiere RT, Kalivas PW. Glutamate release in the nucleus accumbens core is necessary for heroin seeking. J Neurosci (2008) 28:3170-7. doi:10.1523/JNEUROSCI.5129-07.2008.
212. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, et al. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend (2008) 94:191-8. doi:10.1016/j.drugalcdep.2007.11.017.
213. Malone DT, Jongejan D, Taylor DA. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav (2009) 93:91-6. doi:10.1016/j.pbb.2009.04.010.
214. Karniol IG, Takahashi RN, Musty RE. Effects of delta9-tetrahydrocannabinol and cannabinol on operant performance in rats. Arch Int Pharmacodyn Ther (1974) 212:230-7.
215. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) (1982) 76:245-50. doi:10.1007/BF00432554.
216. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci (2005) 76:1307-24. doi:10.1016/j.lfs.2004.10.025.
217. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses (2006) 66:234-46. doi:10.1016/j.mehy.2005.08.026.
218. Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci (2009) 29:14764-9. doi:10.1523/JNEUROSCI.4291-09.2009.
219. Hamelink C, Hampson A, Wink DA, Eiden LE, Eskay RL. Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J Pharmacol Exp Ther (2005) 314:780-8. doi:10.1124/jpet.105.085779.
220. Trouve R, Nahas G, Stuker O, Latour C. Antagonistic effects of two natural cannabinoids on the isolated heart. C R Seances Acad Sci III (1983) 297:191-4.
221. Nahas G, Trouve R. Effects and interactions of natural cannabinoids on the isolated heart. Proc Soc Exp Biol Med (1985) 180:312-6. doi:10.3181/00379727-180-42181.
222. Agrawal A, Neale MC, Prescott CA, Kendler KS. Cannabis and other illicit drugs: comorbid use and abuse/dependence in males and females. Behav Genet (2004) 34:217-28. doi:10.1023/B:BEGE.0000017868.07829.45.
223. Miller NS, Klahr AL, Gold MS, Sweeney K, Cocores JA. The prevalence of marijuana (cannabis) use and dependence in cocaine dependence. N Y State J Med (1990) 90:491-2.
224. Serrano A, Parsons LH. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther (2011) 132:215-41. doi:10.1016/j.pharmthera.2011.06.005.
225. Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction (2006) 101:556-69. doi:10.1111/j.1360-0443.2005.01322.x.
226. Kandel DB, Yamaguchi K, Klein LC. Testing the gateway hypothesis. Addiction (2006) 101:470-2. doi:10.1111/j.1360-0443.2006.01426.x discussion 474-476.
227. Lynskey MT, Vink JM, Boomsma DI. Early onset cannabis use and progression to other drug use in a sample of Dutch twins. Behav Genet (2006) 36:195-200. doi:10.1007/s10519-005-9023-x.
228. Agrawal A, Lynskey MT, Bucholz KK, Martin NG, Madden PA, Heath AC. Contrasting models of genetic co-morbidity for cannabis and other illicit drugs in adult Australian twins. Psychol Med (2007) 37:49-60. doi:10.1017/S0033291706009287.
229. Tomasiewicz HC, Jacobs MM, Wilkinson MB, Wilson SP, Nestler EJ, Hurd YL. Proenkephalin mediates the enduring effects of adolescent Cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry (2012) 72(10):803-10. doi:10.1016/j.biopsych.2012.04.026.
230. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A (2003) 100:6186-91. doi:10.1073/pnas.0931309100.
231. Hariri AR, Tessitore A, Mattay VS, Fera F, Weinberger DR. The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage (2002) 17:317-23. doi:10.1006/nimg.2002.1179.
232. Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry (1990) 147:719-24.
233. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse (1993) 14:169-77. doi:10.1002/syn.890140210.
234. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry (2001) 158:2015-21. doi:10.1176/appi.ajp.158.12.2015.
235. Andersen SL, Napierata L, Brenhouse HC, Sonntag KC. Juvenile methylphenidate modulates reward-related behaviors and cerebral blood flow by decreasing cortical D3 receptors. Eur J Neurosci (2008) 27:2962-72. doi:10.1111/j.1460-9568.2008.06254.x.
236. Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G, et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry (1997) 2:161-8. doi:10.1038/sj.mp.4000247.
237. Ballon N, Leroy S, Roy C, Bourdel MC, Charles-Nicolas A, Krebs MO, et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J (2006) 6:126-30. doi:10.1038/sj.tpj.6500352.
238. Li YC, Korol AB, Fahima T, Nevo E. Microsatellites within genes: structure, function, and evolution. Mol Biol Evol (2004) 21:991-1007. doi:10.1093/molbev/msh073.
239. Benyamina A, Kebir O, Blecha L, Reynaud M, Krebs MO. CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis. Addict Biol (2011) 16:1-6. doi:10.1111/j.1369-1600.2009.00198.x.
240. Barrero FJ, Ampuero I, Morales B, Vives F, De Dios Luna Del Castillo J, Hoenicka J, et al. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J (2005) 5:135-41. doi:10.1038/sj.tpj.6500301.
241. Haughey HM, Marshall E, Schacht JP, Louis A, Hutchison KE. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction (2008) 103:1678-86. doi:10.1111/j.1360-0443.2008.02292.x.
242. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacology (2010) 35:967-75. doi:10.1038/npp.2009.200.
243. Lopez-Moreno JA, Echeverry-Alzate V, Buhler KM. The genetic basis of the endocannabinoid system and drug addiction in humans. J Psychopharmacol (2012) 26:133-43. doi:10.1177/0269881111416689.
244. Clarke TK, Bloch PJ, Ambrose-Lanci LM, Ferraro TN, Berrettini WH, Kampman KM, et al. Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis. Addict Biol (2013) 18(4):702-8. doi:10.1111/j.1369-1600.2011.00346.x.
245. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A (2002) 99:8394-9. doi:10.1073/pnas.082235799.
246. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet (2006) 120:581-8. doi:10.1007/s00439-006-0250-x.
247. Li CS, Milivojevic V, Constable RT, Sinha R. Recent cannabis abuse decreased stress-induced BOLD signals in the frontal and cingulate cortices of cocaine dependent individuals. Psychiatry Res (2005) 140:271-80. doi:10.1016/j.pscychresns.2005.09.002.
248. Foltin RW, Fischman MW, Pippen PA, Kelly TH. Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans. Drug Alcohol Depend (1993) 32:93-106. doi:10.1016/0376-8716(93)80001-U.
249. Lukas SE, Sholar M, Kouri E, Fukuzako H, Mendelson JH. Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. Pharmacol Biochem Behav (1994) 48:715-21. doi:10.1016/0091-3057(94)90338-7.
250. Xi ZX, Spiller K, Pak AC, Gilbert J, Dillon C, Li X, et al. Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology (2008) 33:1735-45. doi:10.1038/sj.npp.1301552.
251. Vlachou S, Nomikos GG, Panagis G. WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Behav Brain Res (2003) 141:215-22. doi:10.1016/S0166-4328(02)00370-4.
252. Vlachou S, Stamatopoulou F, Nomikos GG, Panagis G. Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. Int J Neuropsychopharmacol (2008) 11:905-23. doi:10.1017/S1461145708008717.
253. Li X, Hoffman AF, Peng XQ, Lupica CR, Gardner EL, Xi ZX. Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology (Berl) (2009) 204:1-11. doi:10.1007/s00213-008-1432-0.
254. Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci (2007) 27:791-5. doi:10.1523/JNEUROSCI.4152-06.2007.
255. Soria G, Mendizabal V, Tourino C, Robledo P, Ledent C, Parmentier M, et al. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology (2005) 30:1670-80. doi:10.1038/sj.npp.1300707.
256. Caille S, Parsons LH. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology (2006) 31:804-13. doi:10.1038/sj.npp.1300848.
257. Xi ZX, Gilbert JG, Peng XQ, Pak AC, Li X, Gardner EL. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J Neurosci (2006) 26:8531-6. doi:10.1523/JNEUROSCI.0726-06.2006.
258. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, et al. Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 14:1160-6. doi:10.1038/nn.2874.
259. Luchicchi A, Lecca S, Carta S, Pillolla G, Muntoni AL, Yasar S, et al. Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors. Addict Biol (2010) 15:277-88. doi:10.1111/j.1369-1600.2010.00222.x.
260. Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 64:930-7. doi:10.1016/j.biopsych.2008.08.008.
261. Adamczyk P, McCreary AC, Przegalinski E, Mierzejewski P, Bienkowski P, Filip M. The effects of fatty acid amide hydrolase inhibitors on maintenance of cocaine and food self-administration and on reinstatement of cocaine-seeking and food-taking behavior in rats. J Physiol Pharmacol (2009) 60:119-25.
262. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci (2000) 12:4038-46. doi:10.1046/j.1460-9568.2000.00287.x.
263. Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology (2005) 30:339-49. doi:10.1038/sj.npp.1300568.
264. Miller LL, Ward SJ, Dykstra LA. Chronic unpredictable stress enhances cocaine-conditioned place preference in type 1 cannabinoid receptor knockout mice. Behav Pharmacol (2008) 19:575-81. doi:10.1097/FBP.0b013e32830ded11.
265. Chaperon F, Soubrie P, Puech AJ, Thiebot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) (1998) 135:324-32. doi:10.1007/s002130050518.
266. Lesscher HM, Hoogveld E, Burbach JP, Van Ree JM, Gerrits MA. Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. Eur Neuropsychopharmacol (2005) 15:31-7. doi:10.1016/j.euroneuro.2004.04.003.
267. Corbille AG, Valjent E, Marsicano G, Ledent C, Lutz B, Herve D, et al. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci (2007) 27:6937-47. doi:10.1523/JNEUROSCI.3936-06.2007.
268. Gerdeman GL, Schechter JB, French ED. Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant. Neuropsychopharmacology (2008) 33:2747-59. doi:10.1038/sj.npp.1301648.
269. Filip M, Golda A, Zaniewska M, McCreary AC, Nowak E, Kolasiewicz W, et al. Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine. Pharmacol Rep (2006) 58:806-19.
270. Przegalinski E, Gothert M, Frankowska M, Filip M. WIN 55,212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT(3) receptor function. Eur J Pharmacol (2005) 517:68-73. doi:10.1016/j.ejphar.2005.05.014.
271. Aracil-Fernandez A, Trigo JM, Garcia-Gutierrez MS, Ortega-Alvaro A, Ternianov A, Navarro D, et al. Decreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB(2) receptors. Neuropsychopharmacology (2012) 37:1749-63. doi:10.1038/npp.2012.22.
272. Panlilio LV, Solinas M, Matthews SA, Goldberg SR. Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats. Neuropsychopharmacology (2007) 32:646-57. doi:10.1038/sj.npp.1301109.
273. Gorriti MA, Rodriguez De Fonseca F, Navarro M, Palomo T. Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol (1999) 365:133-42. doi:10.1016/S0014-2999(98)00851-6.
274. Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ. The role of CB1 receptors in psychostimulant addiction. Addict Biol (2008) 13:225-38. doi:10.1111/j.1369-1600.2008.00109.x.
275. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res (2001) 118:61-5. doi:10.1016/S0166-4328(00)00311-9.
276. Vaughn LK, Mantsch JR, Vranjkovic O, Stroh G, Lacourt M, Kreutter M, et al. Cannabinoid receptor involvement in stress-induced cocaine reinstatement: potential interaction with noradrenergic pathways. Neuroscience (2012) 204:117-24. doi:10.1016/j.neuroscience.2011.08.021.
277. Adamczyk P, Miszkiel J, McCreary AC, Filip M, Papp M, Przegalinski E. The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats. Brain Res (2012) 1444:45-54. doi:10.1016/j.brainres.2012.01.030.
278. Vinklerova J, Novakova J, Sulcova A. Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. J Psychopharmacol (2002) 16:139-43. doi:10.1177/026988110201600204.
279. Poncelet M, Barnouin MC, Breliere JC, Le Fur G, Soubrie P. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Berl) (1999) 144:144-50. doi:10.1007/s002130050987.
280. Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci (2000) 3:1073-4. doi:10.1038/80577.
281. Yu LL, Zhou SJ, Wang XY, Liu JF, Xue YX, Jiang W, et al. Effects of cannabinoid CB(1) receptor antagonist rimonabant on acquisition and reinstatement of psychostimulant reward memory in mice. Behav Brain Res (2011) 217:111-6. doi:10.1016/j.bbr.2010.10.008.
282. Ward SJ, Rosenberg M, Dykstra LA, Walker EA. The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse. Drug Alcohol Depend (2009) 105:248-55. doi:10.1016/j.drugalcdep.2009.07.002.
283. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med (2001) 7:1151-4. doi:10.1038/nm1001-1151.
284. Orio L, Edwards S, George O, Parsons LH, Koob GF. A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions. J Neurosci (2009) 29:4846-57. doi:10.1523/JNEUROSCI.0563-09.2009.
285. Daza-Losada M, Minarro J, Aguilar MA, Valverde O, Rodriguez-Arias M. Acute blockade of CB1 receptor leads to reinstatement of MDMA-induced conditioned place preference. Pharmacol Biochem Behav (2011) 100:33-9. doi:10.1016/j.pbb.2011.07.011.
286. Rodriguez-Arias M, Manzanedo C, Roger-Sanchez C, Do Couto BR, Aguilar MA, Minarro J. Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference. Prog Neuropsychopharmacol Biol Psychiatry (2010) 34:166-71. doi:10.1016/j.pnpbp.2009.10.019.
287. Braida D, Iosue S, Pegorini S, Sala M. 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. Pharmacol Res (2005) 51:177-82. doi:10.1016/j.phrs.2004.07.009.
288. Braida D, Sala M. Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. Br J Pharmacol (2002) 136:1089-92. doi:10.1038/sj.bjp.0704825.
289. Anggadiredja K, Nakamichi M, Hiranita T, Tanaka H, Shoyama Y, Watanabe S, et al. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology (2004) 29:1470-8. doi:10.1038/sj.npp.1300454.
290. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) (2004) 175:360-6. doi:10.1007/s00213-004-1825-7.
291. Higuera-Matas A, Soto-Montenegro ML, Del Olmo N, Miguens M, Torres I, Vaquero JJ, et al. Augmented acquisition of cocaine self-administration and altered brain glucose metabolism in adult female but not male rats exposed to a cannabinoid agonist during adolescence. Neuropsychopharmacology (2008) 33:806-13. doi:10.1038/sj.npp.1301467.
292. Fattore L, Martellotta MC, Cossu G, Mascia MS, Fratta W. CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behav Brain Res (1999) 104:141-6. doi:10.1016/S0166-4328(99)00059-5.
293. Sinha R, Fuse T, Aubin LR, O'Malley SS. Psychological stress, drug-related cues and cocaine craving. Psychopharmacology (Berl) (2000) 152:140-8. doi:10.1007/s002130000499.
294. Jarbe TU, Henriksson BG, Ohlin GC. Delta9-THC as a discriminative cue in pigeons: effects of delta8-THC, CBD, and CBN. Arch Int Pharmacodyn Ther (1977) 228:68-72.